Last updated 2026-06-18
Total raised
—
Stage
Pre-Funding
Founded
2018
Headcount
1-10
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences
About
TeloCure aims to develop a gene therapy for hoyeraal-hreidarsson syndrome, an ultra-rare disease characterized by excessively short telomeres which is considered a severe form of dyskeratosis congenita.
Q&A
- What is TeloCure's primary focus?
- TeloCure aims to develop a gene therapy for Hoyeraal-Hreidarsson Syndrome, an ultra-rare disease characterized by excessively short telomeres, which is considered a severe form of dyskeratosis congenita.
- When was TeloCure founded?
- TeloCure was founded in July 2018.
- What is the current status of TeloCure?
- TeloCure is currently inactive and ceased to operate in October 2019.
- Where is TeloCure headquartered?
- TeloCure is headquartered in Ness Ziona, Israel.
- What is TeloCure's primary sector?
- TeloCure's primary sector is Health Tech & Life Sciences.
- What is TeloCure's current funding stage?
- TeloCure is in the Pre-Funding stage.
- How many employees does TeloCure have?
- TeloCure has an employee count in the 1-10 range.
- Who is a key member of TeloCure's team?
- Noam Diamant is a Co-founder & CEO at TeloCure.
Team · 1
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
stealthmodeneurologygenetic-disordersrare-diseasesimmunotherapytherapeutics
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/33312587 |
Identifiers & details
| Founded | 2018-7 |
|---|---|
| Status reason | Non Active, Oct 2019 ceased to operate |